Key result
Transcatheter tricuspid valve interventions improve tricuspid regurgitation severity, functional class, and quality of life, with potential mortality benefit over medical management.
Why the study?
Severe tricuspid regurgitation carries adverse prognosis, but most patients are managed medically because isolated surgery has high in-hospital mortality, leaving an unmet clinical need for transcatheter options.
Do transcatheter tricuspid valve interventions improve outcomes in high-risk patients with severe tricuspid regurgitation compared to medical management?
Do transcatheter tricuspid valve interventions improve outcomes in high-risk patients with severe tricuspid regurgitation compared to medical management?
Transcatheter tricuspid valve interventions are emerging as a safe and effective treatment option for high-risk patients with severe tricuspid regurgitation, though longer-term data is needed.
Answers are grounded in this paper and cite their sources.
TTVIs may address unmet needs in high-risk severe TR; leaves open the need for RCTs to define safety, efficacy, and selection.
PURPOSE OF REVIEW: Severe tricuspid regurgitation is a commonly prevalent valvular heart disease that is an independent adverse prognostic marker. However, the majority of patients with tricuspid regurgitation are managed medically; isolated tricuspid valve surgery is rarely performed, partly owing to high associated in-hospital mortality. Therefore, several transcatheter tricuspid valve interventions (TTVIs) that have been developed over the last few years to address this unmet clinical need. RECENT FINDINGS: The early experience with TTVI has shown that most devices can be safely implanted with excellent rates of technical success and acceptable safety outcomes. Most TTVI recipients have significant improvement in tricuspid regurgitation severity, functional class, and quality of life. Recent retrospective data also suggest mortality benefit of TTVI compared with medical management. There are several issues that need to be addressed prior to widespread adoption of TTVI, including more effective tricuspid regurgitation reduction and need for longer term efficacy data. SUMMARY: TTVI has emerged as an attractive treatment option for management of high-risk patients with tricuspid regurgitation. In this review, we will discuss the anatomical considerations specific to tricuspid valve, patient selection, preprocedure planning, and summarize the current evidence and future perspectives on TTVI.
No takes yet. Share an insight, caveat, or question.
Gupta et al. (2021) conducted a review in Severe tricuspid regurgitation. Transcatheter tricuspid valve interventions (TTVIs) vs. Medical management was evaluated. Transcatheter tricuspid valve interventions improve tricuspid regurgitation severity, functional class, and quality of life, with potential mortality benefit over medical management.
Synapse has enriched 10 related papers. Consider them for comparative context: